# Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

> **NCT05934526** · PHASE3 · COMPLETED · sponsor: **GB002, Inc.** · enrollment: 390 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Placebo
- **DRUG:** Seralutinib
- **DEVICE:** Generic Dry Powder Inhaler

## Key facts

- **NCT ID:** NCT05934526
- **Lead sponsor:** GB002, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-28
- **Primary completion:** 2025-11-27
- **Final completion:** 2025-12-22
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05934526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05934526, "Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05934526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*